NSECredit Rating1 Jul 2026 · 1 Jul 2026, 06:40 pm

Credit Rating

Alembic Pharmaceuticals Limited · APLLTD

✦ AI SummaryRating Change

Alembic Pharmaceuticals Limited has informed the Exchange about the reaffirmation of its credit rating on bank loan facilities and commercial paper by CRISIL Ratings Limited.

Analysis Scores

Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Alembic Pharmaceuticals Limited has informed the Exchange about Credit Rating

Attachments (1)

📄

APLLTD_01072026184020_APL_Intimation_Enhanced_Amount_Rating_Crisil_S.pdf

pdf

Download →
View document text
Date: 1st July, 2026 To, To, The Manager, The Manager, Department of Corporate Services, Listing Department, BSE Limited National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code:533573 NSE Symbol: APLLTD Dear Sir/Madam, Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- Reaffirmation of Credit Rating on Bank Loan Facilities (with enhanced limits) and Commercial Paper With reference to the captioned matter, we wish to inform you that CRISIL Ratings Limited (CRISIL), vide its letter dated 30th June 2026, has reaffirmed its Credit Rating on Bank Loan Facilities (with enhanced limits) and Commercial Paper. The details of the same are given below: Rating Amount No Instrument Rating Action Assigned (Rs. in Crores) Total Bank Loan Rs. 1,100 CRISIL 1. Facilities Reaffirmed (Enhanced from AA+/Stable (Long Term Rating) Rs. 800) 2. Commercial Paper CRISIL A1+ Reaffirmed Rs. 1,100 The rating letters received from CRISIL are attached as an Annexure. We request you to kindly take the same on record. Thanking you, Yours faithfully, For Alembic Pharmaceuticals Limited G Krishnan Chief Financial Officer ALEMBIC PHARMACEUTICALS LIMITED REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229 Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123 CONFIDENTIAL RL/ALBCPSL/398117/BLR/0626/151715 June 30, 2026 Mr. Nilesh Mistry Head - Corporate Finance & Accounts Alembic Pharmaceuticals Limited Alembic Road Vadodara Vadodara - 390003 9925034677 Dear Mr. Nilesh Mistry, Re: Review of Crisil Ratings on the bank facilities of Alembic Pharmaceuticals Limited All ratings assigned by Crisil Ratings are kept under continuous surveillance and review. Please find in the table below the ratings outstanding for the debt instruments/facilities of the company, and the rating actions by Crisil Ratings on the ratings as on date. Total Bank Loan Facilities Rated Rs.1100 Crore (Enhanced from Rs.800 Crore) Long Term Rating Crisil AA+/Stable (Reaffirmed) (Bank-wise details as per Annexure 1) As per our Rating Agreement, Crisil Ratings would disseminate the ratings, along with the outlook, through its publications and other media, and keep the ratings, along with the outlook, under surveillance over the life of the instrument/facility. Crisil Ratings reserves the right to withdraw, or revise the ratings, along with the outlook, at any time, on the basis of new information, or unavailability of information, or other circumstances which Crisil Ratings believes may have an impact on the ratings. Please visit www.crisilratings.com and search with the name of the rated entity to access the latest rating/s. In the event of the company not availing the proposed facilities within a period of 180 days from the date of this letter, a fresh letter of revalidation from Crisil Ratings will be necessary. Crisil Ratings products / activities or ratings of instruments other than securities that are listed or proposed to be listed may fall under the purview of financial sector regulators (FSRs) other than SEBI. In respect of such products / activities or ratings (under the purview of other FSRs such as Reserve Bank of India (RBI), Ministry of Corporate Affairs (MCA), Insurance Regulatory and Development Authority of India (IRDAI), among others), the grievance / dispute redressal and investor protection mechanisms available under SEBI regulations shall not be applicable. A list of products/activities or ratings of instruments falling under the purview of various FSRs along with the names of respective FSRs has been duly disclosed by Crisil Ratings on its website. A link to the same has been provided below for ready reference: https://www.crisilratings.com/en/home/our-business/ratings/regulatory-disclosures/list-of-activities-instruments-and- names-of-regulators.html Should you require any clarification, please feel free to get in touch with us. With warm regards, Yours sincerely, Aditya Jhaver Nivedita Shibu Disclaimer: A rating by Crisil Ratings reflects Crisil Ratings’ current opinion on the likelihood of timely payment of the obligations under the rated instrument, and does not constitute an audit of the rated entity by Crisil Ratings. Our ratings are based on information provided by the issuer or obtained by Crisil Ratings from sources it considers reliable. Crisil Ratings does not guarantee the completeness or accuracy of the information on which the rating is based. A rating by Crisil Ratings is not a recommendation to buy / sell or hold the rated instrument; it does not comment on the market price or suitability for a particular investor. Crisil Ratings has a practice of keeping all its ratings under surveillance and ratings are revised as and when circumstances so warrant. Crisil Ratings is not responsible for any errors and especially states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of its ratings. Crisil Ratings’ criteria are available without charge to the public on the web site, www.crisilratings.com. Crisil Ratings or its associates may have other commercial transactions with the company/entity. For the latest rating information on any instrument of any company rated by Crisil Ratings, please visit www.crisilratings.com or contact Customer Service Helpdesk at Crisilratingdesk@crisil.com or at 1800-267-3850 Director - Crisil Ratings Director - Crisil Ratings Annexure 1 - Bank-wise details of various facility classes (outstanding facilities) Amount (Rs. S.No. Bank Facility Bank Outstanding Rating in Crore) Cash Credit & Working 1 HDFC Bank Limited 200 Crisil AA+/Stable Capital Demand Loan Cash Credit & Working Kotak Mahindra Bank 2 100 Crisil AA+/Stable Capital Demand Loan Limited Cash Credit & Working The Hongkong and Shanghai 3 100 Crisil AA+/Stable Capital Demand Loan Banking Corporation Limited Cash Credit & Working 4 Citibank N. A. 100 Crisil AA+/Stable Capital Demand Loan Cash Credit & Working 5 Axis Bank Limited 100 Crisil AA+/Stable Capital Demand Loan Working Capital Demand 6 State Bank of India 100 Crisil AA+/Stable Loan Working Capital Demand 7 RBL Bank Limited 200 Crisil AA+/Stable Loan Working Capital Demand 8 State Bank of India 200 Crisil AA+/Stable Loan Total 1100 1-5. 100% interchangeability between funded and non-funded Disclaimer: A rating by Crisil Ratings reflects Crisil Ratings’ current opinion on the likelihood of timely payment of the obligations under the rated instrument, and does not constitute an audit of the rated entity by Crisil Ratings. Our ratings are based on information provided by the issuer or obtained by Crisil Ratings from sources it considers reliable. Crisil Ratings does not guarantee the completeness or accuracy of the information on which the rating is based. A rating by Crisil Ratings is not a recommendation to buy / sell or hold the rated instrument; it does not comment on the market price or suitability for a particular investor. Crisil Ratings has a practice of keeping all its ratings under surveillance and ratings are revised as and when circumstances so warrant. Crisil Ratings is not responsible for any errors and especially states that it has no financial liability whatsoever to the subscribers / users / transmitters / distributors of its ratings. Crisil Ratings’ criteria are available without charge to the public on the web site, www.crisilratings.com. Crisil Ratings or its associates may have other commercial transactions with the company/entity. For the latest rating information on any instrument of any company rated by Crisil Ratings, please visit www.crisilratings.com or contact Customer Service Helpdesk at Crisilratingdesk@crisil.com or at 1800-267-3850 Annexure: List of instruments and names of regulators of the instr [Showing first 8,000 characters — download PDF for full document]